News

Public · Published

Organigram Swoops In To Acquire Aurora Cannabis, Topping Curaleaf's Rival Bid – ACB Stock Surges To Over 10-Month Highs

Organigram Global has agreed to acquire Aurora Cannabis for C$561 million ($400 million), or C$7.80 per share, topping Curaleaf's rival bid. Both boards unanimously approved the proposed deal, which is expected to close in January 2027 and awaits Aurora shareholder approval.

Published:

Updated:

What happened

Organigram Global has agreed to acquire Aurora Cannabis for C$561 million ($400 million), or C$7.80 per share, topping Curaleaf's rival bid. Both boards unanimously approved the proposed deal, which is expected to close in January 2027 and awaits Aurora shareholder approval.

Proposed

Global impact / market context

The deal would end a prolonged takeover battle for Aurora. Aurora holders would own roughly 35% of the combined company, which would run five production and distribution facilities and target cost savings. Curaleaf's rejected lower offers signal buyers saw strategic value in Aurora's business.

Analyst inference

Aurora shares jumped over 20% to their highest since December 2025, and Curaleaf rose about 13%, while Organigram slipped 1.3%. The premium to Aurora's unaffected price shows how much the bidding war lifted expectations, and the deal remains conditional pending shareholder approval.

Analyst inference

What to watch

  1. Aurora shareholders are expected to own roughly 35% of the combined company's equity on a fully diluted basis, meaning all shares including those from options and other convertible instruments are counted. Confirmed
  2. Watch whether Curaleaf returns with a higher offer or walks away. Its two rejected bids suggest it wanted Aurora, so a renewed bid could reopen the contest and change the deal terms. Analyst inference
  3. Watch completion of the expected January 2027 closing, which depends on Aurora shareholder approval. Any delay or rejection would leave the takeover battle unresolved and keep both stocks sensitive to new bids. Proposed

Evidence